Imm0306s + soc
Preclinical
Imm0306s + soc is one of 44 therapeutic programs targeting Systemic Lupus Erythematosus. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
328 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Eptanemab
UCBPhase 3
Rituxan
RochePhase 3
Medrol
PfizerPhase 3
Olumiant
Eli LillyPhase 3
Rinvoq
AbbViePhase 3
Stelara
Johnson & JohnsonPhase 3
Gazyva
RochePhase 3
Ocrevus
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Systemic Lupus Erythematosus1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Imm0306s + soc. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]